Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as Hsp90 C-terminal inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 2, 2015, Pages 204-209

  Garg, Gaurav ^a   Zhao, Huiping ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

breast cancer; Heat shock protein 90; Hsp90 C terminal inhibitors; ring constrained novobiocin analogues; structure activity relationship

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; NOVOBIOCIN; TERTIARY AMINE;

ALDOL REACTION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CATALYST; DEACETYLATION; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HEAT SHOCK RESPONSE; HYDROGEN BOND; HYPOTHESIS; IC50; MCF 7 CELL LINE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84922936462     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5004475     Document Type: Article

References (29)

1. Taipale, M.; Jarosz, D. F.; Lindquist, S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 2010, 11, 515-528
2. Chaudhury, S.; Welch, T. R.; Blagg, B. S. J. Hsp90 as a target for drug development ChemMedChem 2006, 1, 1331-1340
3. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket Curr. Med. Chem. 2008, 15, 2702-2717
4. Bishop, S. C.; Burlison, J. A.; Blagg, B. S. Hsp90: a novel target for the disruption of multiple signaling cascades Curr. Cancer Drug Targets 2007, 7, 369-88
5. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100, 57-70
6. Blagg, B. S. J.; Kerr, T. D. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation Med. Res. Rev. 2006, 26, 310-338
7. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 2012, 18, 64-76
8. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer Nat. Rev. Cancer 2005, 5, 761-772
9. Peterson, L. B. B.; Brian, S. J. To fold or not to fold: modulation and consequences of Hsp90 inhibition Future Med. Chem. 2009, 1, 267-283
10. Zhao, H.; Blagg, B. S. J. Inhibitors of the Hsp90 C-terminus. In Inhibitors of Molecular Chaperones as Therapeutic Agents; RSC Drug Discovery Series; RSC: London, U.K., 2013; Vol. 37
11. Davenport, J.; Balch, M.; Galam, L.; Girgis, A.; Hall, J.; Blagg, B.; Matts, R. High-throughput screen of natural product libraries for Hsp90 inhibitors Biology 2014, 3, 101-138
12. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins J. Natl. Cancer Inst. 2000, 92, 242-248
13. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90 J. Am. Chem. Soc. 2006, 128, 15529-15536
14. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 inhibitors identified from a library of novobiocin analogues J. Am. Chem. Soc. 2005, 127, 12778-12779
15. Zhao, H.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E. L.; Brown, D.; Rajewski, R. A.; Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. J. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents J. Med. Chem. 2011, 54, 3839-3853
16. Eskew, J.; Sadikot, T.; Morales, P.; Duren, A.; Dunwiddie, I.; Swink, M.; Zhang, X.; Hembruff, S.; Donnelly, A.; Rajewski, R.; Blagg, B.; Manjarrez, J.; Matts, R.; Holzbeierlein, J.; Vielhauer, G. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells BMC Cancer 2011, 11, 1-16
17. Shelton, S. N.; Shawgo, M. E.; Matthews, S. B.; Lu, Y.; Donnelly, A. C.; Szabla, K.; Tanol, M.; Vielhauer, G. A.; Rajewski, R. A.; Matts, R. L.; Blagg, B. S. J.; Robertson, J. D. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells Mol. Pharmacol. 2009, 76, 1314-1322
18. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity J. Org. Chem. 2008, 73, 8901-8920
19. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines J. Org. Chem. 2008, 73, 2130-2137
20. Burlison, J. A.; Blagg, B. S. J. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery Org. Lett. 2006, 8, 4855-4858
21. Huang, Y.-T.; Blagg, B. S. J. A library of noviosylated coumarin analogues J. Org. Chem. 2007, 72, 3609-3613
22. Zhao, H.; Reddy Kusuma, B.; Blagg, B. S. J. Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity ACS Med. Chem. Lett. 2010, 1, 311-315
23. Zhao, H.; Yan, B.; Peterson, L. B.; Blagg, B. S. J. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition ACS Med. Chem. Lett. 2012, 3, 327-331
24. Zhao, H.; Blagg, B. S. J. Novobiocin analogues with second-generation noviose surrogates Biol. Med. Chem. Lett. 2013, 23, 552-557
25. Kusuma, B. R.; Khandelwal, A.; Gu, W.; Brown, D.; Liu, W.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors Biol. Med. Chem. 2014, 22, 1441-1449
26. Donnelly, A. C.; Zhao, H.; Reddy Kusuma, B.; Blagg, B. S. J. Cytotoxic sugar analogues of an optimized novobiocin scaffold MedChemComm 2010, 1, 165-170
27. Kyle Hadden, M.; Hill, S. A.; Davenport, J.; Matts, R. L.; Blagg, B. S. J. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold Biol. Med. Chem. 2009, 17, 634-640
28. Huang, X. Y.; Shan, Z. J.; Zhai, H. L.; Li, L. N.; Zhang, X. Y. Molecular design of anticancer drug leads based on three-dimensional quantitative structure-activity relationship J. Chem. Inf. Model. 2011, 51, 1999-2006
29. Matts, R. L.; Dixit, A.; Peterson, L. B.; Sun, L.; Voruganti, S.; Kalyanaraman, P.; Hartson, S. D.; Verkhivker, G. M.; Blagg, B. S. J. Elucidation of the Hsp90 C-terminal inhibitor binding site ACS Chem. Biol. 2011, 6, 800-807